Boston Life Sciences, Inc. to Participate in the 2007 BIO CEO & Investor Conference

HOPKINTON, Mass., Feb. 7  /PRNewswire-FirstCall/ -- Boston Life Sciences, Inc. (NASDAQ:BLSI) today announced that Peter Savas, Chairman and Chief Executive Officer of Boston Life Sciences, Inc., will be presenting a Company update at the BIO CEO & Investor Conference on Tuesday, February 13, 2007 from 10:30 am - 11:10 am EST.  The conference is being held from February 12-14 at the Waldorf-Astoria in New York City, NY.

BLSI also announced that Mark Hurtt, Chief Medical Officer of Boston Life Sciences, Inc., will be participating on a panel at the BIO CEO & Investor Conference titled "CNS: Parkinson's Disease - Biotech Breakthroughs", which will run from 9:30 am - 10:55 am EST on Monday, February 12.  This panel will explore technologies that could enable early and accurate diagnosis and identify an "at risk" population as well as emerging therapies focused on currently untreated symptoms and novel, potentially disease-modifying therapies.

The Boston Life Sciences Company presentation on February 13th will be available by webcast.  Access to the webcast will be available within the Investor Relations section of the Boston Life Sciences website at http://www.bostonlifesciences.com/.

About Boston Life Sciences, Inc.

Boston Life Sciences, Inc. (BLSI) is engaged in the research and clinical development of diagnostic and therapeutic products for central nervous system (CNS) disorders. ALTROPANE(R) molecular imaging agent is in Phase III clinical trials for the diagnosis of Parkinson's Disease (PD) and Phase II clinical trials for the diagnosis of Attention Deficit Hyperactivity Disorder (ADHD). Cethrin(R), a recombinant-protein-based drug designed to promote nerve repair after acute spinal cord injury, has reported positive interim results in a Phase I/IIa clinical trial. The company's research and pre-clinical CNS programs include Inosine for the treatment of spinal cord injury and stroke, a DAT blocker for the treatment of Parkinson's disease, and a second generation technetium-based molecular imaging agent for PD and ADHD. BLSI's current research collaborations include Harvard Medical School and Children's Hospital Boston.

   Contact:  Meredith Patin -- 508-497-2360 ext 239
             Boston Life Sciences, Inc.
             

DATASOURCE: Boston Life Sciences, Inc.



CONTACT:  Meredith Patin of Boston Life Sciences, Inc., [phone],

ext 239, or  



Web site:  http://www.bostonlifesciences.com/ 

Copyright